[September 16, 2014] |
|
electroCore to Present at Major European Headache Meeting (EHMTIC) on the Success of Its Non-Invasive Vagus Nerve Stimulation Therapy for Cluster Headache
BASKING RIDGE, N.J. --(Business Wire)--
This weekend, at the international headache meeting in Copenhagen
(EHMTIC*), electroCore will be presenting full data on their PREVA
study, a randomized, multi-center trial across several European
countries, which showed that preventative use of non-invasive vagus
nerve stimulation (nVNS) can substantially reduce the frequency of
cluster headache attacks (i.e., by 43.4%) versus the control group (the
current standard of care, which experienced only a 12% reduction).
Three poster presentations will provide full details of the PREVA trial
and include
A report on - the randomized phase
A report on the open label phase
An analysis of quality of life impact
On Saturday evening electroCore is hosting a satellite symposium with
three eminent headache specialists.
-
Professor Jean Schoen, Director of the Headache Research Unit at the
University of Liège, Belgium, who will provide an overview of
Neuromodulation and the role of non-invasive vagus nerve (nVNS)
stimulation.
-
Dr. Charly Gaul, Director of the Migraine and Headache Clinic
Königstein, Germany and the principle investigator of the PREVA trial
who will comprehensively explore the use of nVNS in the prevention of
cluster headache.
-
Professor Stephen Silberstein, Director of the Thomas Jefferson
Headache Centre at the Thomas Jefferson University and Hospitals
Philadelphia, who will present data on nVNS in the prevention of
chronic migraine.
electroCore, a US based company, has developed non-invasive Vagus Nerve
Stimulation (nVNS) therapies, which are self-administered by patients
for the treatment of multiple conditions in neurology, psychiatry,
respiratory and other fields. Initial focus is on primary headache
(migraine and cluster headache), with trials continuing in gastric
motility disorders and epilepsy.
In Europe, electroCore's nVNS technology has a CE mark for primary
headache, bronchoconstriction, epilepsy, gastric motility disorders, and
anxiety and depression. It also has regulatory approval for the acute
and/or prophylactic treatment of cluster headache, migraine and
medication overuse headache in South Africa, India, New Zealand,
Australia, Colombia, Brazil and Malaysia, and in Canada for cluster
headache. US approval is anticipated in 2015.
www.electrocoremedical.com
*European Headache and Migraine and Trust International
Congress
Note to Editors:
electroCore was founded in 2005 and is based in New Jersey, USA. The
therapy is currently being launched through healthcare professionals in
Canada, Germany, UK, and other parts of Europe with US approval
anticipated in 2015.
[ Back To TMCnet.com's Homepage ]
|